CTOs on the Move

NightstaRx

www.nightstarx.com

 
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nightstarx.com
  • 81 Hartwell Ave Suite 100
    Lexington, MA USA 02421
  • Phone: +44 7817 868300

Executives

Name Title Contact Details

Funding

NightstaRx raised $45M on 06/30/2017

Similar Companies

Innovative Seating

Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.

Momenta Pharmaceuticals

Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.

Kyowa Kirin North America

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible.

PanTheryx

PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.